AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34018341
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo gel)
Trial: 36398439
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus exemestane (25 mg/day)
Trial: 35170192
Drug: bremelanotide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bremelanotide (3 times daily for 15 days)
Trial: 35170192
Drug: bremelanotide (twice-daily)
RxNorm normalized name: clindamycin
DrugBank: Bremelanotide (DB11653)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bremelanotide (twice-daily)
Trial: 35170192
Drug: bremelanotide (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bremelanotide (3 times daily)
Trial: 35893857
Drug: Micronutrient tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient tablets (Tablets)
Trial: 36451623
Drug: Light touch
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light touch therapy (LTT) plus repositioning therapy
Trial: 33509413
Drug: Contingency management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contingency management (CM) implemented by trained staff of opioid treatment programs (OTPs)
Trial: 33509413
Drug: New methods
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New methods of medication delivery implemented by OTPs
Trial: 33838579
Drug: Algorithm Guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm Guided Treatment started with escitalopram (AGT-E)
Trial: 33838579
Drug: Algorithm Guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Algorithm Guided Treatment started with mirtazapine (AGT-M)
Trial: 34343545
Drug: Maxillofacial and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxillofacial and oral massage (MOM)
Trial: 32162741
Drug: Topical red
RxNorm normalized name: acid red 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical red clover oil (20 drops twice a day for 4 weeks)
Trial: 32162741
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (control group, 20 drops twice a day for 4 weeks)
Trial: 35984574
Drug: Mottling <
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mottling < 6 hours and lactate ≥ 2 mmol/L
Trial: 38264360
Drug: Dulaglutide (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide (1.5 mg)
Trial: 34797778
Drug: 3-g gluten
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-g gluten challenge
Trial: 37429432
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin infusion
Trial: 34349116
Drug: Treatment type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment type and anxiety symptoms
Trial: 34645287
Drug: Endovascular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular treatment plus usual care
Trial: 34472698
Drug: Comparators (placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparators (placebo, sitagliptin 100 mg, liraglutide 1.8 mg)
Trial: 37713133
Drug: guselkumab 100
RxNorm normalized name: guselkumab 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: guselkumab 100 mg
Trial: 32794582
Drug: D/L‐3‐hydroxybutyrate (hyperketotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D/L‐3‐hydroxybutyrate (hyperketotic condition)
Trial: 32599497
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Protocol (LDP)
Trial: 32599497
Drug: Conventional Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Dose Protocol (CDP)
Trial: 33709856
Drug: Inhaled Glycopyrronium
RxNorm normalized name: glycopyrronium Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Glycopyrronium Bromide 6.25 µg BID
Trial: 33709856
Drug: Inhaled Glycopyrronium
RxNorm normalized name: glycopyrronium Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Glycopyrronium Bromide 12.5 µg BID
Trial: 32897319
Drug: Mindfulness‐Based Stress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness‐Based Stress Reduction (abbreviated to four weekly 90‐minute sessions)
Trial: 32493462
Drug: Two sequences
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sequences of two daily tDCS sessions over 5 days (one active and one sham)
Trial: 32229495
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg)
Trial: 33693863
Drug: CGRP-targeted monoclonal
RxNorm normalized name: CGRP
DrugBank: Calcitonin gene-related peptide (DB06379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CGRP-targeted monoclonal antibodies (CGRP-targeted mAbs) as add-on therapy to onabotulinumtoxinA
Trial: 32881699
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (infants who did not receive antibiotics)
Trial: 32114185
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy for insomnia (CBTI)
Trial: 32799029
Drug: Sleep restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep restriction therapy (SRT)
Trial: 38115004
Drug: Dapagliflozin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (10 mg daily)
Trial: 32170355
Drug: Topical co-delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical co-delivery of platelet rich fibrin (PRF) and tranexamic acid (TA)
Trial: 32170355
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (combined intravenous and topical TA)
Trial: 32462642
Drug: Intraoperative tibia
RxNorm normalized name: Tilia extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative tibia fractures treatment
Trial: 32160368
Drug: Topical dimethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dimethyl sulfoxide (DMSO) 50% solution
Trial: 32160368
Drug: Tretinoin 0.5%
RxNorm normalized name: Tretinoin 0.5% Topical solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tretinoin 0.5% cream
Trial: 36186784
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous injection of vitamin C (200 mg/kg/24 h) for 4 days
Trial: 33887662
Drug: Real rTMS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real rTMS with physical therapy (PT)
Trial: 33887662
Drug: Real cTBS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real cTBS with physical therapy (PT)
Trial: 33887662
Drug: Sham cTBS
RxNorm normalized name: Syn023 component ctb-011
DrugBank: Zamerovimab (DB17766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham cTBS with physical therapy (PT)
Trial: 34009177
Drug: Endoscopic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic treatment
Trial: 33394989
Drug: L-T mode
RxNorm normalized name: (T,G)-A-L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-T mode at output power of 60 W and 84 W
Trial: 33394989
Drug: L mode
RxNorm normalized name: GenTeal Moderate Ophthalmic Drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L mode
Trial: 33394989
Drug: L-T mode
RxNorm normalized name: (T,G)-A-L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-T mode
Trial: 35366419
Drug: AJM300 (960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AJM300 (960 mg) administered orally, three times daily for 8 weeks
Trial: 34549819
Drug: Topical Antioxidants
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Antioxidants (AO) 2.0%
Trial: 34666379
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg twice daily) starting from 14 to 20 weeks' gestation until delivery
Trial: 35292944
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg twice daily)
Trial: 34666379
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose aspirin (80 mg/day) and calcium (1 g/day)
Trial: 37173784
Drug: Citicoline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline treatment
Trial: 38273252
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ibuprofen
Trial: 32866967
Drug: Metformin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2 g daily)
Trial: 34121413
Drug: MEDI6012 (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI6012 (intravenous doses of 24, 80, 240, and 800 mg)
Trial: 34121413
Drug: MEDI6012 (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI6012 (subcutaneous doses)
Trial: 36438959
Drug: Bright Light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright Light Therapy (BLT)
Trial: 35900607
Drug: Teriparatide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teriparatide (20 µg sc daily for 48 weeks)
Trial: 35900607
Drug: Alendronate (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (70 mg oral weekly for 48 weeks)
Trial: 33909860
Drug: 1.23% acidulated
RxNorm normalized name: Nupro APF 1.23% Acidulated Phosphate Fluoride Gel (Bubblegum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.23% acidulated phosphate fluoride (APF) gel
Trial: 33109390
Drug: PCV13 2
RxNorm normalized name: Streptococcus pneumoniae serotype 14 capsular antigen diphtheria CRM197 protein conjugate vaccine
DrugBank: Streptococcus pneumoniae type 14 capsular polysaccharide diphtheria CRM197 protein conjugate antigen (DB10289)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCV13 2 + 1 (received pneumococcal conjugate vaccine 13 valent at 2, 4 and 12 months)
Trial: 38927991
Drug: Nivolumab monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab monotherapy
Trial: 32150484
Drug: Aster glehni
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aster glehni Extract (AGE) 480 mg/day
Trial: 36049557
Drug: Oral everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral everolimus (days 1-3: 7.5 mg qd, days 4-5: 5.0 mg qd)
Trial: 35790011
Drug: Transdermal buprenorphine
RxNorm normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Transdermal buprenorphine solution (TBS) 8 mg (0.4 ml) for cats 1.2 to 3 kg and 20 mg (1 ml) for cats >3 to 7.5 kg, applied topically 1–2 h prior to surgery.
Trial: 32102803
Drug: Cognitive Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioural Therapy (CBT) in addition to usual treatment for 16 weeks
Trial: 32102803
Drug: Talking control
RxNorm normalized name: Take Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Talking control in addition to usual treatment for 16 weeks
Trial: 36075249
Drug: ABX464 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABX464 50 mg
Trial: 32704050
Drug: Self-administered questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaire including the Dutch Musculoskeletal Questionnaire and Modified Nordic Musculoskeletal Questionnaire
Trial: 35914662
Drug: Omalizumab 300
RxNorm normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab 300 mg subcutaneously every 4 weeks for 24 weeks
Trial: 36398042
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate at 40 mg·kg‐1 of actual body weight
Trial: 33073523
Drug: Dapagliflozin 10
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 10 mg once daily for 13 weeks
Trial: 34391006
Drug: 1 treatment
RxNorm normalized name: Selenium Sulfide 1% Topical application Shampoo [SELSUN BLUE 2 IN 1 TREATMENT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 treatment course of rTMS
Trial: 37522226
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg
Trial: 33547980
Drug: Single 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 400 μg dose of anti-GnRH vaccine (G1)
Trial: 33547980
Drug: Two 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 400 μg doses of anti-GnRH vaccine (G2)
Trial: 33547980
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) - 1 mL saline 0.9%
Trial: 35599990
Drug: Online group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online group intervention consisting of 12 weekly modules based on cognitive-behavioral methods
Trial: 34936268
Drug: Herb-separated moxibustion
RxNorm normalized name: serrated swimming crab, cooked preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herb-separated moxibustion on navel combined with Ningmitai capsule
Trial: 34936268
Drug: Ningmitai capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ningmitai capsule
Trial: 37428547
Drug: TAU (treatment-as-usual)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU (treatment-as-usual)
Trial: 33169383
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine without intubation
Trial: 33169383
Drug: Availability of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Availability of essential drugs
Trial: 34236131
Drug: Skin-to-skin contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin-to-skin contact (SSC) for one hour daily for five weeks
Trial: 37344262
Drug: V114 (15-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V114 (15-valent pneumococcal conjugate vaccine)
Trial: 33666305
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg risperidone
Trial: 39319904
Drug: Double antibiotic
RxNorm normalized name: Double Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Double antibiotic paste (DAP)
Trial: 38854963
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy alone
Trial: 34292199
Drug: Web-based lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based lower back exercise intervention, performed at least twice a day, four times a week for 8 weeks
Trial: 32337738
Drug: Antipsychotics discontinued
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotics discontinued >90 days
Trial: 35797219
Drug: additional anthracycline-containing
RxNorm normalized name: methacycline
DrugBank: Metacycline (DB00931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: additional anthracycline-containing chemotherapy
Trial: 35014613
Drug: Maternal oral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal oral vitamin D supplementation 1,20,000 IU/month for 12 months
Trial: 35014613
Drug: Maternal oral
RxNorm normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maternal oral vitamin D supplementation 12,000 IU/month for 12 months
Trial: 33975010
Drug: Dual combination
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual combination therapy, specifically carbapenem-polymyxin regimen
Trial: 34446156
Drug: Colchicine 0.5
RxNorm normalized name: colchicine 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 0.5 mg once daily
Trial: 33213529
Drug: Zilucoplan (32.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilucoplan (32.4 mg subcutaneously daily) plus IV ceftriaxone (2g daily for 14 days) and standard of care
Trial: 33213529
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus IV ceftriaxone (2g daily for 1 week)
Trial: 34511184
Drug: Vadadustat 150
RxNorm normalized name: vadadustat 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vadadustat 150 mg with sodium ferrous citrate
Trial: 34511184
Drug: Vadadustat 150
RxNorm normalized name: vadadustat 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vadadustat 150 mg with ferric citrate hydrate
Trial: 34511184
Drug: Vadadustat 150
RxNorm normalized name: vadadustat 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vadadustat 150 mg with sucroferric oxyhydroxide
Trial: 34511184
Drug: Vadadustat 150
RxNorm normalized name: vadadustat 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vadadustat 150 mg with ferrous sulfate
Trial: 33882893
Drug: Telemonitoring of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemonitoring of adherence to inhalation therapies, weekly home spirometry, video-conferencing, self-management app, professional telephone coaching.
Trial: 36202557
Drug: MitraClip implantation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitraClip implantation plus guideline‐directed medical therapy (GDMT)
Trial: 33386332
Drug: 2-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose regimen (0, 12)
Trial: 33386332
Drug: 3-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-dose regimen (0, 2, 6)
Trial: 33386332
Drug: 2-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose regimen (0, 6)
Trial: 34201450
Drug: Standard Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Group and Enhanced Group received 20 smoking-related messages over 2 weeks; Enhanced Group received an extra 6 oral health-related messages for one week.
Trial: 35226559
Drug: Edoxaban 15
RxNorm normalized name: edoxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edoxaban 15 mg
Trial: 33016374
Drug: Rivastigmine (capsules)
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine (capsules)
Trial: 33016374
Drug: Rivastigmine (patch)
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine (patch)
Trial: 35717820
Drug: ICI-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI-based therapy (monotherapy or combination)
Trial: 35717820
Drug: VEGF inhibitor
RxNorm normalized name: Vegf receptor 2 kinase inhibitor i
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VEGF inhibitor monotherapy
Trial: 35717820
Drug: mTOR inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mTOR inhibitor monotherapy
Trial: 38231570
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (treatment as usual).
Trial: 34738161
Drug: Bolus group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus group (0.5 mg penehyclidine injected before anesthesia)
Trial: 34738161
Drug: Infusion group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion group (0.25 mg penehyclidine injected before anesthesia and another 0.25 mg infused after surgery)
Trial: 32811681
Drug: Sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemotherapy followed by radiation (CT‐RT)
Trial: 32811681
Drug: Sequential radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential radiation followed by chemotherapy (RT‐CT)
Trial: 32086373
Drug: Abstinence-contingent wage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abstinence-contingent wage supplements
Trial: 32654156
Drug: Placebo, weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, weekly subcutaneous administration for 65 weeks
Trial: 35142000
Drug: Complex Oral
RxNorm normalized name: vitamin B complex Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex Oral Semantic Fluency (COSEF) task
Trial: 34305642
Drug: Nocturnal Oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nocturnal Oxygen Therapy (NOT) at 3 L/min
Trial: 34395624
Drug: 1 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg/kg dose of nitroglycerin
Trial: 34395624
Drug: 2 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg/kg dose of nitroglycerin
Trial: 39698942
Drug: Non-steroidal anti-inflammatory
RxNorm normalized name: Non-steroidal anti-inflammatory agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroidal anti-inflammatory drugs (NSAIDs)
Trial: 33662334
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anti-IL-21 and liraglutide
Trial: 35238894
Drug: Pemafibrate 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemafibrate 0.2 mg twice a day